Citation: Adams JD (2017) Chronic Pain -Can It Be Cured? J Pharm Drug Devel 4(1): 105 Chronic pain is currently treated with several drugs and therapies that can be helpful, but usually do not cure chronic pain. In fact, many drug therapies make the pain worse or are toxic to the patient. Chronic pain treatment frequently involves oral or injected drugs because the perception is that chronic pain comes from an internal source. Chronic pain, and all other forms of pain, should be treated in the skin. Mechanisms of induction of chronic pain will be discussed and skin targets for the treatment and cure of chronic pain will be presented.
Introduction
List of Abbrivations: COX2: cyclooxygenase-2; NSAIDs: nonsteroidal anti-inflammatory drugs; IL-17 interleukin-17: TRP: transient receptor potential cation channel; γδT cells: skin resident T cells; TNFα: tumor necrosis factor α; AMPA α: amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid None of the drugs or procedures currently used actually cure chronic pain. Perhaps better internal sites for drug or radiofrequency wave administration can be found that will actually cure chronic pain. Perhaps better drug delivery systems will be able to provide better therapy that will cure chronic pain.
The Opioid Crisis
The healthcare community is either so confident in current therapy or knows of nothing better, that opioids continue to be prescribed for chronic pain. Opioids are addictive, cause tolerance and kill patients due to respiratory depression and seizures. In 2017, the Centers for Disease Control report that 15,000 patients died from oxycodone, methadone and hydrocodone use. Patients who are tolerant to these drugs search for stronger alternatives including heroin and fentanyl. Heroin is about twice the potency of morphine. Fentanyl is about 100 times more potent than morphine. In 2017, 15,000 patients died from heroin injection. Heroin use has become a middle class epidemic. In 2017, 20,000 patients died from fentanyl injection. Fentanyl use is also a middle class epidemic. This adds up to about 50,000 patients dying yearly from opioid use for pain.
When tolerance to opioids occurs, the dose is increased. As the dose escalates, opioids begin to cause pain, opioid induced hyperalgesia. This increase in pain does not occur in every patient. The mechanism of opioid induced hyperalgesia is under Volume 4 | Issue 1 investigation, but may involve the induction of chemokines in the skin [1] . Clearly, in order to cure chronic pain, opioid administration must be stopped.
The NSAIDs Crisis
Much less reported in the literature is the NSAIDs crisis. The FDA increased black box warnings for all NSAIDs in July 2015. The black box warnings indicate that NSAIDs cause heart attacks, strokes and other thrombus problems. The FDA indicates that the risk of heart attack or stroke is increased by at least 10% by NSAIDs. It can be assumed that all people in the US use NSAIDs sometime during any year. Therefore, it can be calculated that NSAIDs are responsible for at least 24,000 deaths from heart attack and 14,000 deaths from stroke. The Centers for Disease Control report that NSAIDs cause 100,000 ulcers yearly, of which 16,500 die. This adds up to 54,500 deaths every year from NSAIDs. The US public might be alarmed to learn that the NSAID pain relievers sold over the counter are so dangerous.
Mechanisms Involved in Chronic Pain
Damage to the skin results in the release of chemokines ( Figure 1 ) by damaged neurons, dendritic cells and other cells [2, 3] . Neuronal chemokines bind to their specific G protein coupled receptors on macrophages, which activates macrophages and induces cyclooxygenase-2 (COX2, 4). Inflammatory factors are then produced by macrophages. Macrophages secrete chemokines that bind to their specific receptors on sensory neurons and increase the transactivation of transient receptor potential cation (TRP) channels, which enhances pain [5] . TRP channels are the most abundant pain receptors in the body and are mostly located on skin sensory neurons [6] . Prostaglandins, including PGI2 and PGE2, secreted by macrophages and other cells, interact with prostaglandin receptors, such as EP2 and IP, on sensory neurons causing pain, and increase the activation of TRP channels enhancing pain. Prostaglandins also up regulate the production of chemokines by dendritic cells [7] . Opioid peptides secreted in the skin by leukocytes and other cells induce the production of chemokines and their receptors [1] . γδT cells are skin resident T cells that secrete IL-17, which induces chemokine production. IL-23 and IL-1β secreted by macrophages stimulate IL-17 production [8, 9] . Tumor necrosis factor α (TNFα) released by damaged keratinocytes stimulates IL-17 production [10] . Chemokines released by damaged dendritic cells activate γδT cells [11] . All skin sensory neurons use glutamate as their primary neurotransmitter. Calcium permeable α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors on peripheral sensory neurons regulate chronic pain [12] . Other extracellular molecules involved in chronic pain in the skin include: bradykinin, histamine, nerve growth factor, 4-hydroxynonenal, ATP, 5,6-epoxyeicosatrienoic acid, 5-hydroxyeicosa-tetraenoic acid, calcitonin gene-related peptide, high mobility group protein B1. All of these factors are released following damage, pain and inflammation. This can establish chronic pain in the skin. Chronic pain involves a cyclic, self-perpetuating mechanism in which chemokines stimulate production of prostaglandins and IL-17. Prostaglandins and IL-17 then stimulate chemokine production.
Figure 1:
Chronic pain mechanisms -A damaged sensory nerve terminal in the skin releases chemokines (C) that attract macrophages, bind to C receptors (CR) and induce COX2 in macrophages. Macrophages secrete C that transactivate neuronal TRP channels. Prostaglandins (P) are released by macrophages and bind to their receptors (PR) to cause pain. Resident T cells in the skin bind C and secrete interleukin-17 (I) that induces more C production. Figure modified from [15] 
Potential Targets for Curing Chronic Pain
Clearly, there are several potential targets for drug therapy in chronic pain in the skin. The skin is where pain is sensed. The safest and most effective treatment for pain is in the skin [13, 14] . Chronic pain is probably caused by the mechanisms discussed above in the skin. Treating the skin may be the best approach to curing chronic pain.
Of course, the brain and brain stem are involved in chronic pain mechanisms also. The involvement of the brain and brain stem in chronic pain has been adequately discussed in several publications [1, 5] . Despite many years of attempting to cure chronic pain with systemically administered drugs that penetrate into the brain and brain stem, there is no cure. In fact, the most notable effects of the systemic approach to chronic pain treatment has been the deaths of over 100,000 patients yearly and the hospitalization of thousands more.
COX2 is induced in the skin during chronic pain. COX2 inhibition in the skin can be easily accomplished with methyl salicylate that can be applied to the skin and penetrates into the skin. Temporary inhibition of skin COX2 by methyl salicylate does not cure chronic pain. It may be better to down regulate COX2 in the skin in order to cure chronic pain [15] . Several natural products are known to penetrate into the skin after topical application and down regulate COX2 in the skin, including sesquiterpenes [15] and flavonoids such as eupafolin [16] .
TRP channels are targets that may lead to cures for chronic pain. There are several products on the market that are applied to the skin and relieve pain by inhibiting TRP channels. These products contain monoterpenoids, 10 carbon compounds from plants, which penetrate into the skin. However, inhibition of TRP channels by these products is inadequate to cure chronic pain, perhaps because too few monoterpenoids are used. Distinct TRP channels exist in non-overlapping populations of skin sensory neurons. There are at least 28 different TRP channels, each with different sensitivities to monoterpenoids [6] . A mixture of monoterpenoids may provide better pain therapy through inhibition of many different TRP channels. Rather than using a silver bullet to cure chronic pain, a cocktail of monoterpenoids should be used. Monoterpenoids can inhibit IL-17 production in the skin [17] . When IL-17 is no longer produced, chemokine synthesis may stop. This may cure chronic pain.
Curing chronic pain might be possible through down regulation of chemokine or opioid peptide production in the skin. IL-23 and IL-1β down regulation might cure chronic pain. Calcium permeable AMPA receptors may be targets for chronic pain cure.
The endocannabinoid, anandamide, activates cannabinoid-1 receptors on keratinocytes. This binding inhibits the mechanistic target of rapamycin, which is a protein kinase. The end-result is that neighboring resident T cells decrease their secretion of IL-17 [18] . Various plant medicines made from Cannabis sativa contain cannabinoids and are currently on the market for application to the skin. Perhaps one of these products cures chronic pain.
